Griffith Hack announces four promotions, including two principal elevations
Griffith Hack is proud to announce the promotion of four team members, including the elevation of Dr James-Robert Cram and Kerry Dick to principal
Read more
Australian Government again denied $325m damages claim in clopidogrel injunction dispute
The Full Court of the Federal Court of Australia has dismissed the Commonwealth’s appeal against a 2020 decision to deny it $325m in damages in a dispute relating to the antiplatelet drug clopidogrel.
Read more
Griffith Hack will be attending AUTM’s 2023 Annual Meeting in Austin, Texas
Griffith Hack is proud to sponsor the 2022 edition of the Fragment-Based Drug Discovery Down Under Conference.
Read more
Are you patent ready? IP guidance for life sciences researchers
Whether you are an academic or industry-based researcher, the question is the same: when is the right time to file a patent application?
Read more
Griffith Hack sponsors Fragment-Based Drug Discovery Down Under Conference 2022
Griffith Hack is proud to sponsor the 2022 edition of the Fragment-Based Drug Discovery Down Under Conference.
Read more
Karen Sinclair talks synthetic biology on the From Idea to Intellectual Property podcast
Karen Sinclair joins host Lisa Leong on the From Idea to Intellectual Property podcast series to discuss the emerging trends and key issues in the area of synthetic biology.
Read more
Spotlight Series: Regenerative Medicine – Part 2
Welcome to the second article of our Spotlight Series on one of the most exciting frontiers of scientific research and innovation, regenerative medicine.
Read more
Changes to how influencers can promote therapeutic goods in Australia
The Therapeutic Goods Administration has set out new guidelines that govern how influencers can promote products on social media in return for payment or free products or services from brands.
Read more
Federal Budget 2022: What’s in it to accelerate Australia’s innovation agenda?
We discuss the key measures in Australia’s 2022-23 federal budget that could help drive innovation, research commercialisation and business growth.
Read more
From idea to inception and beyond: Important learnings from female biotech founders
Female biotech founders took centre-stage at AusBiotech 2021 with the leaders of some of Australia’s most innovative start-ups coming together to discuss their experiences in the commercial scientific world.
Read more
Saving grace: Options if you disclose your invention without a patent application
Publicly disclosing new technology before a patent application has been filed can jeopardise patent coverage – but there are options available to you in the event of disclosure.
Read more
Virus filtration patent gets clean bill of health
In a recent decision of the Australian Patent Office, a patent application directed to a membrane for filtering biological products was upheld following opposition.
Read more
Extending the 12-month grace period for filing patent applications – what you need to know
Can the 12-month grace period for filing your patent application be extended? Yes, it can – but subject to the facts.
Read more
Why are embryonic stem cells not able to be patented in Australia?
Despite not being specifically excluded under s18 of the Australian Patents Act, technology utilising embryonic stem cells is not able to be patented in Australia. Why is this so?
Read more
Spotlight Series: Regenerative Medicine – Part 1
The first in a five-part series on one of the most exciting frontiers of scientific research and innovation, regenerative medicine.
Read more
Draft roadmap for Australian regenerative medicine released for comment
AusBiotech has released a draft strategic roadmap for a new regenerative medicine Catalyst.
Read more
Guidance on patenting diagnostics in Australia: Ariosa Diagnostics v Sequenom
Federal Court confirms that a non-invasive diagnostic test for prenatal conditions is patentable subject matter in Australia.
Read more
Ono: Broader is not always better
Why is patent term extension is so important to companies developing and commercialising new pharmaceutical substances?
Read more
CRISPR-Cas9 Update: Collision of Trends in IP and Life Sciences
CRISPR-Cas9 genome editing may not just be the greatest scientific breakthrough of this century, but also provides many lessons on patenting life science technologies.
Read more